← Back to patent-cliff list
CAS 1655504-61-2
tert-Butyl 4-[5-carbamoyl-6-(4-phenoxyphenyl)pyridin-2-yl]piperidine-1-carboxylate
Codes: (IX)965082-1-a,(IX)965082-1-b
Application context (from source-drug indications)
Marginal zone B-cell lymphomaOrelabrutinibMantle cell lymphomaOrelabrutinibChronic lymphocytic leukaemiaOrelabrutinibImmune thrombocytopenic purpuraOrelabrutinibSystemic lupus erythematosusOrelabrutinibMultiple sclerosisOrelabrutinib
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Orelabrutinib | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
2,6-Dichloronicotinonitrile→2,6-Dichloronicotinamide→2,6-Dichloropyridine-3-carboxylic acid→(3-Phenoxyphenyl)boronic acid→4,4,5,5-Tetramethyl-2-(3-phenoxyphenyl)-1,3,2-dioxaborolane→6-Chloro-2-(4-phenoxyphenyl)pyridine-3-carboxamide→N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester→tert-Butyl 5-carbamoyl-6-(4-phenoxyphenyl)-3',6'-dihydro[2,4'-bipyridine]-1'(2'H)-carboxylate→tert-Butyl 4-[5-carbamoyl-6-(4-phenoxyphenyl)pyridin-2-yl]piperidine-1-carboxylate→2-(4-Phenoxyphenyl)-6-(piperidin-4-yl)pyridine-3-carboxamide→2-(4-Phenoxyphenyl)-6-(piperidin-4-yl)pyridine-3-carboxamide hydrogen chloride→Acryloyl chloride
tert-Butyl 4-[5-carbamoyl-6-(4-phenoxyphenyl)pyridin-2-yl]piperidine-1-carboxylate→3-Nitropropanal→3-Oxo-3-(4-phenoxyphenyl)propanamide→(2Z)-5-Nitro-2-(4-phenoxybenzoyl)pent-2-enamide→tert-Butyl 4-oxopiperidine-1-carboxylate→tert-Butyl 4-[(3Z)-4-carbamoyl-1-nitro-5-oxo-5-(4-phenoxyphenyl)pent-3-en-1-yl]-4-hydroxypiperidine-1-carboxylate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.